### 5.0 <u>510(k) Summary</u>

Submitter:

Capnia, Inc.

2445 Faber Place, Suite 250

Palo Alto CA 94303 (650) 213-8444 phone (650) 213-8383 fax

**Contact Person:** 

Julie Blacklock

Director Quality and Regulatory Affairs

(650) 213-8444 ext 41 julie@capnia.com

Date Prepared:

01/13/2014

Trade Name:

CoSense<sup>TM</sup> ETCO Monitor

Common Name:

Carbon Monoxide Monitor

**Classification Name:** 

Carbon Monoxide Gas Analyzer

(21 CFR 868.1430, Product Code CCJ)

**Predicate Devices:** 

CoSense™ CO Monitor (K121768) and

CO-STAT™ End Tidal Breath Analyzer (K974805)

(reference predicate)

**Device Description:** 

The CoSense ETCO Monitor is a battery-operated carbon

monoxide (CO) monitor. It uses an infrared capnometer to

detect the end-tidal portion of the breath and an

electrochemical carbon monoxide sensor to measure the end-tidal breath CO concentration. The device consists of a portable unit with software controlled menu (date, time, patient identification, measurement time of monitoring), single-use nasal cannula, replaceable CO Sensor, and a

battery charger/power supply.

### **Indications for Use:**

The CoSense ETCO Monitor is indicated for the monitoring of carbon monoxide from endogenous sources (including hemolysis) and exogenous sources (including CO poisoning and smoke inhalation) in exhaled breath. The end tidal carbon monoxide level can be used for the monitoring of carbon monoxide in medical conditions in which the rate of hemolysis may be relevant. It is also for use in smoking cessation programs and can be used for the screening of CO poisoning and smoke inhalation.

# Technological Characteristics:

The CoSense ETCO Monitor uses the identical performance specifications (accuracy, range, and resolution), software algorithms, sensors, and accessories as our predicate device, the CoSense CO Monitor. The CoSense ETCO Monitor also has similar performance specifications (accuracy, range, and resolution) as the reference predicate, CO-STAT End Tidal Breath Analyzer.

Comparison to Predicate Device (K121768) and Reference Predicate (K974805):

	Capnia CoSense ETCO Monitor (Subject Device)	Monitor	Natus CO-STAT, End Tidal Breath Analyzer (Reference Predicate Device)
510(k) Number	K130036	K121768	K974805
Manufacturer	Capnia, Inc.	Capnia, Inc.	Natus Medical, Inc.
. Classification	Class II	Class II	Class II
Product Code	CCJ	CCJ	CCJ
Regulation	21 CFR 868.1430	21 CFR 868.1430	21 CFR 868.1430
Indications for Use	The CoSense ETCO Monitor is indicated for the monitoring of carbon monoxide from endogenous sources (including hemolysis) and exogenous sources	The CoSense CO Monitor is indicated for the monitoring of Carbon Monoxide from endogenous and exogenous sources in exhaled breath. It is for use in smoking	The Natus Breath Analyzer is intended for non-invasive, quantitative measurement of respiratory rate, end tidal carbon dioxide concentration, and end tidal carbon monoxide (corrected for background

Capnia, Inc.

· · · · · · · · · · · · · · · · · · ·			
	Capnia CoSense	Capnia CoSense CO  Monitor	Natus CO-STAT End Tidal Breath Analyzer
	<ul> <li>A contract to the contract to the</li></ul>	la di	[
	(Subject Device)	(Predicate Device)	(Reference Predicate Device)
Service Committee Committe	4 1 1 00	<u> </u>	
	(including CO	cessation programs	carbon monoxide)
	poisoning and	and can be used for	concentration in the breath.
	smoke inhalation)	the screening of CO poisoning and smoke	The analyzer is intended for use with neonates, children,
1	in exhaled breath.	inhalation. It is for use	and adults breathing
	The end tidal	by health	spontaneously.
	carbon monoxide	professionals.	The analyzer measures the
	level can be used	protosofonaisi	carbon monoxide
	for the monitoring	,	concentration in end tidal
	of carbon monoxide		breath, as an indicator of
	in medical		the blood level of COHb.
	conditions in which		The level of COHb (and
	the rate of		consequently the
-	hemolysis may be	,	concentration of carbon
	relevant. It is also		monoxide in the end tidal
	for use in smoking		breath) can be affected by
	cessation programs		endogenous sources (for
	and can be used for	•	example the rate of
	the screening of CO		hemolysis), exogenous
	poisoning and		sources (for example,
	smoke inhalation.		combustion engine exhaust), or in some cases
			both. The COHb level,
			elevated or normal, can be
			used in the diagnosis of
			medical conditions in
			which the rate of hemolysis
			may be relevant, and in the
			monitoring of patient
	•		populations affected by the
		'	rate of hemolysis. The
			analyzer is also indicated
			for use in respiratory status
			evaluation, whenever measurement of respiratory
			rate and end tidal carbon
			dioxide concentration are
			desired.
			The analyzer is intended for
•			use under the direction of a
			physician in hospitals and a
			variety of health care
			settings.
	<u> </u>	<u> </u>	<u> </u>

	Capnia CoSense ETCO Monitor (Subject Device)	Capnia CoSense CO Monitor (Predicate Device)	Natus CO-STAT End Tidal Breath Analyzer (Reference Predicate Device)
Patient Interface	Nasal cannula	Nasal cannula	Nasal cannula
Dimensions (LxWxH)	246mm x 197mm x 68mm	244mm x 183mm x 58mm	222mm x 292mm x 152mm
Weight	3.31bs	2.31bs	12lbs
Materials -			And the second of the second o
CO Sensor Cell Type	Electrochemical	Electrochemical	Electrochemical
Cannula	Non-DEHP PVC	Non-DEHP PVC	Not Available
Battery	Li-Ion	Li-Ion	AC Power connected to UPS
Performance Specifications			
Accuracy	+/- 10% or +/-0.5ppm whichever is greater	+/- 10% or +/-0.5ppm whichever is greater	+/- 10% or +/-0.3ppm (whichever is greater) at 8-60 bpm
CO Measurement Range	1.0 – 25.0ppm	1.0 – 25.0ppm	0-25 ppm
Resolution	0.1 ppm	0.1 ppm	0.1 ppm
Measurement Time	Less than 5 minutes	Less than 5 minutes	90% of final reading in 30 seconds; total time unknown
Sample Collection	Collection of a normal breath using a disposable nasal cannula	Collection of a normal breath using a disposable nasal cannula	Collection of a normal breath using a disposable nasal cannula
Modes	Expired	Expired	Expired
Device Shelf Life	1 year before servicing	1 year before servicing	l year before servicing
CO Sensor Shelf Life	6 months	6 months	30 days before calibration
Cannula Shelf Life	8 months	8 months	Not Available
Screen	LCD	LCD	Not Available
Software/ Hardware	Analog and digital electronics with microprocessor	Analog and digital electronics with microprocessor	Not Available

	Capnia CoSense ETCO Monitor (Subject Device)	Capnia CoSense CO Monitor (Predicate Device)	Tidal Breath Analyzer
Power Source	Rechargeable Battery	Rechargeable Battery	AC

Non-clinical Performance Data:

The design and performance specifications are identical to our predicate device. No additional non-clinical performance data is provided.

Clinical Performance Data:

An analysis of published clinical data was conducted. This analysis was performed on the uses of other FDA-cleared CO monitoring devices for measurement of CO in screening of CO poisoning, smoke inhalation and detection of hemolysis. Results provide objective evidence that the functional and performance specifications of CoSense device are similar to the devices in the published studies, specifically the CO-STAT End Tidal Breath Analyzer, and are within the range of accuracy, measurement, and resolution of the devices currently used clinically for detection of endogenous and exogenous sources of elevated CO.

**Conclusion:** 

Capnia considers the revised CoSense ETCO Monitor device to be equivalent to our predicate device and the reference predicate listed above. This conclusion is based upon the devices' similarities in indications for use and identical principles of operation, technology, and performance. The accuracy, measurement range, and resolution specifications are unchanged from our predicate CoSense device. These performance specifications are similar to the CO-STAT End Tidal Breath Analyzer (reference predicate). The proposed CoSense device indication is also similar to the indication for CO-STAT End Tidal Breath Analyzer, as both indications use hemolysis as examples of endogenous CO. Published clinical data and previous design verification data demonstrate that the device is equivalent to our predicate device.



Food and Drug Administration 10903 New Hampshire Avenue Document Control Center ~ WO66-G609 Silver Spring, MD 20993-0002

January 14, 2014

Capnia, Incorporated
Ms. Julie Blacklock
Director, Quality and Regulatory Affairs
2445 Faber Place, Suite 250
Palo Alto, CA 94303

Re: K130036

Trade/Device Name: CoSense™ ETCO Monitor

Regulation Number: 21 CFR 868.1430

Regulation Name: Carbon Monoxide Gas Analyzer

Regulatory Class: II Product Code: CCJ

Dated: December 13, 2013 Received: December 16, 2013

Dear Ms. Blacklock:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <a href="http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm">http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm</a>. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <a href="http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm">http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm</a> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,



Erin I. Keith, M.S.
Acting Director
Division of Anesthesiology, General Hospital,
Respiratory, Infection Control and
Dental Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

## DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration

## **Indications for Use**

Form Approved: OMB No. 0910-0120 Expiration Date: January 31, 2017 See PRA Statement on last page.

10(k) Number (if known)				
130036				
evice Name				
oSense ETCO Monitor				
dications for Use (Describe)				
The CoSense ETCO Monitor is indicated for the monitoring of carbon monoxide from endogenous sources (including hemolysis) and exogenous sources (including CO poisoning and smoke inhalation) in exhaled breath. The end tidal carbon monoxide level can be used for the monitoring of carbon monoxide in medical conditions in which the rate of hemolysis may be relevant. It is also for use in smoking cessation programs and can be used for the screening of CO poisoning and smoke inhalation.				
		·		
		•		
·				
	•	·		
	·			
		•		
		<u> </u>		
ype of Use (Select one or both, as applicable)	Over-The-Counter Use (21 CFR 8	(01 Subpart C)		
Prescription Use (Part 21 CFR 801 Subpart D)	Over-The-Counter Cae (21 C) 11			
PLEASE DO NOT WRITE BELOW THIS LINE - CO	ONTINUE ON A SEPARATE PAGE I	F NEEDED.		
FOR FDA U	1			
Concurrence of Center for Devices and Radiological Health (CDRH) (	Signature)			
Novan II-Datale CZAR				
Nayan J. Patel S				
2014.01.1318.05.50-05'00'		4-2		

This section applies only to requirements of the Paperwork Reduction Act of 1995.

#### \*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW,\*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."